Endolytix

unknown

Stage

About

Endolytix is developing lyticeuticals, a new class of drugs combining biological therapeutics with an advanced drug delivery platform to target non-tuberculous mycobacterial infections, aiming to improve treatment efficacy and reduce side effects compared to current therapies.

Explore Endolytix's full profile on Brouky

Funding rounds, investor list, and risk signals — unlock with a subscription.